
Evolus (EOLS) Stock Forecast & Price Target
Evolus (EOLS) Analyst Ratings
Bulls say
Evolus is a buy, with a positive outlook on their stock. The company's recent guidance reaffirms revenue and growth projections for 2026, with an expected increase in contribution from their injectable HA gel products. In addition, their long-term outlook suggests strong revenue growth and healthy EBITDA margins. Evolus' differentiated strategy and targeted marketing towards millennials positions them to maintain their market share despite competitive entrants. While potential risks exist, Evolus' solid performance in previous downturns and their expanding product portfolio supports a positive outlook.
Bears say
Evolus is a performance beauty company with commercially available injectable neurotoxins and hyaluronic acid (HA) gels. Key risks to our Buy rating include potential supply chain disruptions, competition from larger players, and dilution. However, we continue to hold a positive view on Evolus' positioning and expect the launch of the new product Sculpt to drive future growth. Additionally, the company's "bundling" strategy and discounts should help to capture market share from competitors like Voluma. Despite these strengths, we have a negative outlook on Evolus' stock due to potential risks and challenges in the competitive and regulatory landscape.
This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.
Evolus (EOLS) Analyst Forecast & Price Prediction
Start investing in Evolus (EOLS)
Order type
Buy in
Order amount
Est. shares
0 shares